Zhi Tong Cai Jing·2025-08-19 00:42Core Viewpoint - Rongchang Biologics (09995) has entered into a licensing agreement with Santen Pharmaceutical (China) Co., Ltd. for the RC28-E injection, granting Santen exclusive rights for development, production, and commercialization in Greater China and several Southeast Asian countries, while retaining global rights outside this region [1][2] Group 1: Licensing Agreement Details - The licensing agreement will commence on August 18, 2025, and will remain effective unless terminated early according to its terms [1] - Rongchang will receive a non-refundable upfront payment of 250 million RMB, up to 520 million RMB in development and regulatory milestone payments, and up to 525 million RMB in sales milestone payments [1] - Additionally, the company will earn a tiered sales royalty based on product sales in the licensed territories, ranging from high single-digit to double-digit percentages [1] Group 2: Product Information and Clinical Trials - RC28-E injection is a self-developed drug targeting VEGF/FGF dual pathways for treating ocular neovascular diseases [2] - The Phase II clinical trial results for RC28-E in treating diabetic macular edema (DME) were presented at the ARVO 2025 conference, showing significant improvements in best-corrected visual acuity (BCVA), reduction in central subfield thickness (CST), and effective alleviation of macular edema [2] - In 2023, the company initiated Phase III clinical trials for RC28-E in treating wet age-related macular degeneration (wAMD) and diabetic macular edema [2]